On March 7, 2025, the District Court for the District of New Jersey entered a Stipulation and Order of Dismissal Without Prejudice in view of ...

The US Food and Drug Administration (FDA) has approved Celltrion’s biosimilars referencing Amgen’s bone disease therapy ...

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz ...

Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...

On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

We recently compiled a list of the 11 Best Undervalued Stocks to Invest in Now. In this article, we are going to take a look ...

Sandoz is one of the largest biosimilars players in the world and we believe it is well-positioned to benefit from the fast pace of growth the market is expected to enjoy over the next decade. Sandoz ...

Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt ...